[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Sharifi et al., 2016 - Google Patents

Efficacy of locally manufactured sofosbuvir and daclatasvir (Sovodak) in combination with ribavirin in treating patients with chronic hepatitis c and cirrhosis in Iran …

Sharifi et al., 2016

View PDF
Document ID
3539561416349490276
Author
Sharifi A
Haj-Sheykholeslami A
Poustchi H
Golzari R
Merat S
Malekzadeh R
Nateghi A
Publication year
Publication venue
Govaresh

External Links

Snippet

Background: Interferon-free treatments for hepatitis C have been recently available. They can cure over 95% of patients within 12 weeks without significant side effects. A combination of daclatasvir and sofosbuvir has been particularly useful as it is effective against all …
Continue reading at govaresh.org (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides

Similar Documents

Publication Publication Date Title
Odenwald et al. Viral hepatitis: Past, present, and future
Yu et al. 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations
Aman et al. Current status and future directions in the management of chronic hepatitis C
Gentile et al. Efficacy and safety of sofosbuvir in the treatment of chronic hepatitis C: the dawn of a new era
RU2007105354A (en) APPLICATION OF THE COMBINATION OF CYCLOSPORIN AND PEGILIATED INTERFERON FOR TREATMENT OF HEPATITIS C (HCV)
Coppola et al. Treatment of chronic hepatitis C in patients with HIV/HCV coinfection
Leung Management of viral hepatitis C
De Nicola et al. Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis
Ballester et al. Hepatitis C virus antibodies and other markers ofblood-transfusion-transmitted infection in multi-transfused Cuban patients
Sharifi et al. Efficacy of locally manufactured sofosbuvir and daclatasvir (Sovodak) in combination with ribavirin in treating patients with chronic hepatitis c and cirrhosis in Iran–preliminary report
Abbas Hepatitis D in pakistan
Bacon et al. Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders
Rockstroh HCV cure for everyone or which challenges remain?
Liaw Viral hepatitis in Taiwan: status in the 1990s
Mahmood et al. Viral Hepatitis in Hemodialysis: An update
Sato et al. Hepatitis B surface antigen decline during sofosbuvir and ribavirin therapy in hepatitis B inactive carriers who were co-infected with hepatitis C
Gedik et al. Chronic Hepatitis B Reactivation Subsequent to Chronic Hepatitis C Treatment: A Case Report
de Knegt HCV treatment in liver transplantation: timing is the challenge
Cheung et al. Liver abnormalities in the immunosuppressed
Yesmembetov et al. First case in Kazakhstan of successful therapy with 2 consecutive direct-acting antiviral regimens in a patient with hepatitis C virus-induced decompensated liver cirrhosis on a liver transplant wait list
Kurniawan Pangenotypic Direct Acting Antivirals Treatment for Chronic Hepatitis C Infection
Zacharakis et al. Reactivation of hepatitis B virus during treatment of hepatitis C genotype 3 with daclatasvir and sofosbuvir in a patient with dual infection of hepatitis B and hepatitis C virus
Shankar Treatment of Hepatitis C virus infection
Ukpong et al. PRO: patients with decompensated cirrhosis listed for liver transplantation should be treated pretransplant
Franchini Is time to treat for HCV all the HIV/HCV co-infected hemophiliacs?